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Improving pain management in elderly
patients with dementia: validation of the
Doloshort observational pain assessment
scale
SIR—More than half of older adults report pain affecting
their quality of life [1]. Self-assessment cannot be imple-
mented in patients with limited communication abilities due
to severe dementia [2, 3]. To address this issue, standardised
observational pain scales have been designed but they may
be relatively lengthy and their validity has not always been
verified. A very brief validated tool could greatly enhance
pain evaluation in busy clinical practices and could also
help shorten more comprehensive geriatric and oncological
assessments of such patients.
In a prior study, we demonstrated that Doloplus-2 cor-
related with self-assessment and had adequate internal con-
sistency and test–retest reliability. We constructed a short
version of Doloplus-2, Doloshort, which includes the five
items that were significantly associated with the visual ana-
logue scale (VAS) score in a multiple regression model [4, 5].
We conducted the present prospective study to examine the
validity of Doloshort and confirm its ease of use.
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Table 1. Patient’s characteristics
CDR = 0 CDR = 1 CDR = 2 CDR = 3
No dementia Mild dementia Moderate dementia Severe dementia Total
38 cases 23 cases 33 cases 21 cases 115 cases P
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (mean, SD) 79.0 ± 9.4 81.2 ± 7.6 82.8 ± 6.9 85.0 ± 6.7 81.6 ± 8.1 0.226†
Gender (men/women) 14/24 13/10 19/14 8/13 54/61 0.992‡
Type of dementia: (n, %) 0.000‡
Alzheimer disease 10 13 8 31
Mixed dementia 11 15 6 32
Vascular dementia 2 5 4 11
Other causes 0 0 3 3
Mini-Mental Status Examination (mean, SD) 28.3 ± 1.6 22.4 ± 2.7 10.5 ± 2.3 3.2 ± 1.8 16.3 ± 7.8 0.000†
Number of co-morbidities (mean, SD) 1.4 ± 1.5 1.8 ± 0.9 1.5 ± 1.1 1.2 ± 1.0 1.5 ± 1.1 0.316§
Number of patients reporting pain (n, %) 29 (76) 18 (78) 28 (85) 20 (95) 95 (83) 0.351‡
Aetiology of pain: (n, %) 0.120‡
Osteoarthritis of joints 10 (34) 11 (61) 17 (61) 11 (55) 49 (52)
Back pain (osteoporosis or ostheoarthritis) 7 (24) 6 (33) 8 (29) 5 (25) 26 (27)
Skin lesion 4 (14) 1 (6) 1 (3) 3 (15) 9 (9)





Hundred and fifteen consecutively hospitalised French-
speaking patients over the age of 65 years followed by the
pain consultation (n: 81) or admitted to a specialised dementia
unit (n: 34) were included. Exclusion criteria were delirium,
acute psychiatric symptoms, end of life care and severe sen-
sory impairment. Mini-Mental Status Examination, and the
dementia rating scale (CDR), was used in all cases to rate cog-
nitive status. The CDR assigns cognitive function to five lev-
els defined as no dementia (CDR= 0), questionable dementia
(CDR = 0.5), mild dementia (CDR = 1), moderate dementia
(CDR = 2) and severe dementia (CDR = 3). The patients
underwent a complete neuropsychological evaluation and
appropriate laboratory testing including neuroimaging.
Seventy-seven (67%) patients met DSMIV criteria for
dementia [6].
Age, gender distribution, pain prevalence and pain aeti-
ology were not significantly different in individuals with and
without dementia (Table 1).
Doloshort is an observational pain scale reflecting pain
during usual care; it is completed by the nurse in charge of
the patient after appropriate discussion with other involved
team members (see Appendix 1 in the supplementary data
on Age and Ageing online) [4, 5]. Self-assessment was com-
pleted with one study investigator in a quiet room. Patients
were asked whether they experienced pain at the time of
the assessment and to indicate the level of pain they were
currently experiencing with the visual analogue scale (VAS).
The patients were considered to have understood the VAS if
they were able to explain its use and could correctly indi-
cate which position corresponded to no pain at all and
which position to the most severe pain. Study investiga-
tors and the nursing staff were blinded to each other’s
assessments.
Convergent validity: bivariate correlational analysis using
Kendall’s tau statistic was used to assess the strength of the
association between pain intensities measured by Doloshort
and completed VAS scales. Convergent validity was said to
be present, if there was at least a strong correlation (Kendall’s
tau >0.5 or <−0.5) [7].
Internal consistency: the Cronbach alpha was calculated to
examine the homogeneity of Doloshort.
Discriminant validity was established with two sub-
samples of patients. Divergent validity was said to be present
if therewas less thanminor correlationbetween twomeasures
(Kendall’s tau <0.3 or >−0.3) [7]. In 15 patients without
dementia, the Doloshort score was compared to measures of
anxiety, depression and appetite derived from the Edmonton
Symptom Assessment System (ESAS) completed the same
day by the patient. The ESAS consists of nine visual ana-
logue scales measuring common symptoms in palliative care
[8]. Furthermore, in 20 patients with moderate to severe
dementia, the Doloshort score was compared to the Pitts-
burgh Agitation Scale (PAS) score determined by the team
in charge of the patient [9]. The PAS assesses agitation in
patients with dementia.
Sensitivity to change of Doloshort was evaluated in a sub-
sample of 34 patients with moderate to severe chronic pain.
The first assessment was completed the day before the intro-
duction of opioids (Day 1). The secondwas completed 3 days
after their introduction (Day 4). After converting all scales to
percent scores (no pain = 0% and maximum pain = 100%),
the Wilcoxon matched-pairs signed-ranks test was used to
evaluatewhether both assessmentswere statistically different.
All analyses were performed with the Stata 9.2 statistical
package. The study protocol was approved by the local ethics
committee, and all study participants or appropriate surro-
gates gave their informed consent. Scores in text represent
mean (± standard deviation) unless stated otherwise.
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Table 2. Pain intensity measured by visual analogue scale (VAS) and Doloshort
CDR = 0 CDR = 1 CDR = 2 CDR = 3
No dementia Mild dementia Moderate dementia Severe dementia Total
38 cases 23 cases 33 cases 21 cases 115 cases
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patients that demonstrated good comprehension of VAS (n, %) 38 (100) 23 (100) 29 (88) 7 (33) 97 (84)
Patients demonstrating good comprehension of VAS who were 29 (76) 18 (78) 28 (85) 3 (14) 78 (68)
in pain (n (%))
VAS intensity of pain (median (interquartile range))a 4 (4) 4 (3) 5 (3) 6 (2) 5 (3)
Doloshort intensity (median (interquartile range)) 3 (4) 8 (4) 5.5 (4.1) 6 (2) 4.5 (4)
aOnly patients that demonstrated good comprehension of VAS are included.
Results
Fifty-nine (77%) patients with dementia demonstrated good
comprehension of the VAS. The administration of the
Doloshort was possible in all 115 patients and took 5.0 min-
utes (±0.9) (see Table 2).
Convergent validity: Among patients demonstrating good
comprehension of the VAS, convergent validity was estab-
lished between pain intensity on the VAS and the Doloshort
score. Kendall’s tau-b was 0.523 with an asymptotic stan-
dard error (ASE) = 0.052. The strength of the correlation
was similar in patients with (0.548 (ASE: 0.067)) and without
dementia (0.445 (ASE: 0.112)).
Internal consistency was adequate for all items (Cron-
bach alpha: 0.73) and similar in cognitively intact (0.68) and
dementia patients (0.71).
Discriminant validity: A score above 3 on the anxiety,
depression and appetite sub-scores of the ESAS was present
in respectively 7, 7 and 11 of the 15 patients without demen-
tia. Themean scores were, respectively, 2.3 (±2.1), 3.3 (±2.4)
and 5.3 (±2.8); Kendall’s tau-b (ASE) between these scores
and the Doloshort were: 0.031 (0.258), 0.248 (0.219) and
0.207 (0.252).
Twelve of the 20 patients with dementia had a PAS greater
than 0 (mean 2.7 ± 2.5). Kendall’s tau-b between Doloshort
and PAS was 0.139 (ASE = 0.155).
Sensitivity to change was established in a sub-sample of
34 patients with moderate to severe chronic pain in whom
opioid therapy was initiated. The intensity of pain measured
by the Doloshort was 6.4 ± 2.6 on Day 1 and 3.3 ± 2.3 on
Day 4 (P < 0.001).
A score ≥3 on Doloshort had a sensitivity of 81.5%
and a specificity of 70.5% for the detection of pain, with an
area under the ROC curve of 0.76; this threshold correctly
classified 76 of 100 patients.
Discussion
The Doloshort was easy to use, very quick to complete, cor-
related well with self-assessment and reached desired internal
consistency levels for a new scale [10].
A strength of our study was the use of a self-assessment
pain scale as a gold standard for patients that could still com-
municate. Although use of the VAS in dementia is controver-
sial, we previously demonstrated its reliability in our popula-
tion using standardised simplified instructions designed for
use with cognitively impaired patients [11–14].
Although Doloshort has fewer items, its sensitivity
and specificity were comparable to the longer Doloplus-2.
Doloshort was also able to measure changes in pain inten-
sity and discriminate pain from behavioural symptoms, anxi-
ety and depression. Importantly, Doloshort scores decreased
after treatment with opioid analgesics confirming its validity
for pain evaluation.
However, several limitations of our study should be
kept in mind. Doloshort could only be compared to self-
assessment in patients who understood the VAS, and it is
possible that Doloshort performances may be different in
patients who cannot communicate anymore. Unfortunately,
in such cases there is no available gold standard [15–17]. Also,
Doloshort was completed by nurses in charge of the patient
who were not blinded to treatment status; this could have
affected pain rating in patients receiving analgesics (placebo
use was ruled out for ethical reasons and filming a patient
during an entire shift was not possible).Finally, the study
was performed in a hospitalised older population with a high
prevalence of pain; Doloshort’s performance may be differ-
ent in other settings. Further studies are needed to confirm
the generalisability of our findings and to compareDoloshort
to other observational pain scales in multiple populations.
Key points
 What is known: older patients with dementia commonly
experience pain but often cannot communicate it. A brief,
observation-based, validated tool would greatly enhance
pain control in this rapidly growing population.
 What this study adds: the Doloshort is a concise and
reliable clinical pain assessment tool that is easy to use in
patients with dementia and may be particularly useful in
daily care.
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Outdoor and indoor falls as predictors of
mobility limitation in older women
SIR-–Falls in old age often cause physical injuries, which may
lead to hospitalisation and institutionalisation [1]. However,
whether falls in general have an impact on mobility decline
has been little studied [2, 3]. It has been suggested that out-
door falls are more common among healthy and active older
people, whereas indoor falls are often related to intrinsic risk
factors, such as poor health and impaired balance [4–6]. As
poor health and low functional ability are known to be risk
factors for both indoor falls [4, 5] andmobility disability [7], it
can be hypothesised that, compared to outdoor falls, indoor
falls are more likely to be associated with mobility decline.
However, to date it is not known whether indoor and out-
door falls in old age have a different impact on mobility.
The objective of this study was to determine the association
of outdoor and indoor falls with the incidence of mobility
limitation in older women.
Methods
A total of 434 women aged 63–76 from the Finnish Twin
Study on Aging [8] participated in the baseline examinations.
Subsequently, falls were followed up for 1 year, and 2 years
thereafter mobility limitation was re-examined. The incident
mobility limitationwas defined as the onset ofmajor difficulty
or inability in walking 2 km among those without difficulties
at the baseline. The criteria for participation in this study
were the ability to walk 2 km without major difficulties at
the baseline, complete information about the occurrence and
location of falls during the fall surveillance, and follow-up
information on mobility limitation (n = 376).
At baseline, the presence of chronic conditions and use
of prescribed medications were documented according to
757
